Introduction
The aim of this study was to evaluate local and systemic breast cancer control by comparing the risk of relapse in breast cancer patients in [2003] [2004] with that in 1972-1979 and in 1980-1986 . Materials and methods About 8,570 women diagnosed with invasive breast cancer in [2003] [2004] were selected from the populationbased Netherlands Cancer Registry and compared with 133 patients treated in 1972-1979 and 174 in 1980-1986 . Five-year risk of relapse was calculated by the Kaplan-Meier method. Cox-proportional hazard models were applied to adjust for tumour size, nodal status and age at diagnosis.
Results

Patients diagnosed in 2003-2004
had smaller tumours and a less advanced nodal stage than patients diagnosed in 1972 -1986 . In 1972 -1979 , 1980 -1986 , treatment included mastectomy in 94%, 72% and 47%; postmastectomy radiotherapy in 75%, 70% and 30%; chemotherapy in 9%, 14% and 37% and hormonal therapy in 3%, 3% and 42% of patients, respectively. Fiveyear risk of locoregional and distant recurrence decreased from 37% and 34% to 15%, respectively. The 5-year risk of second primary breast cancer did not differ and was 1%, 4% and 2%, respectively. The improved relapse-free survival in patients di- 
Conclusion
Over the last decades, local breast cancer therapies have become less rigorous, whereas systemic therapy use has increased. Simultaneously, the risk of breast cancer relapse has tremendously decreased. Future novel therapies may lead to such small additional decreases in relapse rates, while the long-term side effects in breast cancer survivors will increase.
Introduction
The breast cancer relapse rate is the key outcome when evaluating local and systemic disease control achieved by primary breast cancer management. Changing relapse rates may have implications for patient management and post-treatment follow-up. In contrast to breast cancer mortality, population-based studies on the time trend in relapse-free survival are rare and generally focus on locoregional recurrence 1, 2 , second primary breast cancer 3,4 or distant metastasis 5, 6 separately, instead of studying overall time trends on relapse-free survival. Relapse rate estimates derived from randomized controlled trials (RCTs) may differ from daily practice, as trials are usually carried out in specialized clinics. Patients and physicians participating in a trial are likely to be more motivated, and patient care is expected to be of higher quality 7, 8 . For that reason, population-based outcome research is of pivotal importance to assess the real impact of innovations after translation in daily practice.
The purpose of this populationbased study was to determine the risk of relapse in breast cancer patients treated with curative intent diagnosed in 2003-2004 and in 1972-1986. 
Materials and methods
This work conforms to the values laid down in the Declaration of Helsinki (1964) . The protocol of this study has been approved by the relevant ethical committee of the Netherlands Cancer Registry. Of patients who had a second primary breast cancer diagnosed within 3 months of the first breast cancer, the tumour with the highest Nottingham prognostic index 12 was included for further analyses.
Breast cancer relapse was defined as a local or regional recurrence, distant metastasis or second primary breast cancer 13 . Relapses diagnosed within 3 months were considered to be diagnosed simultaneously.
Data analyses
To examine the time trend in patient, tumour and treatment characteristics and breast cancer relapse rates, the historical cohort was divided into two groups. Analyses were consequently reported for three periods: 1972-1979, 1980-1986 and 2003-2004 Metastasis in 1-3 ipsilateral axillary lymph node(s), and/or in ipsilateral internal mammary nodes with microscopic metastasis detected by sentinel lymph node dissection but not clinically apparent pN2 Ipsilateral axillary nodes containing metastatic tumour and fixed to one another or to other structures Metastasis in 4-9 ipsilateral axillary lymph nodes or in clinically apparent ipsilateral internal mammary lymph node(s) in the absence of axillary lymph node metastasis pN3 Ipsilateral supraclavicular or infraclavicular nodes containing tumour or oedema of the arm Metastasis in 10 or more ipsilateral axillary lymph nodes; or in clinically apparent ipsilateral internal mammary lymph nodes in the presence of one or more positive axillary lymph nodes; or in more than three axillary lymph nodes with clinically negative, microscopic metastasis in internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes The hazard ratio of 5-year risk of relapse in 1980-1986 and 2003-2004 versus 1972-1979 was adjusted for age at diagnosis, tumour size, nodal status and tumour histology using Cox-proportional hazard modelling.
The SAS system was used to perform the analyses (release 9.2; SAS Institute Inc., Cary, NC, USA).
Results
Patient and tumour characteristics
Patient, tumour and treatment characteristics by period of diagnosis are presented in Table 3 ). Smaller tumour size and no lymph node involvement were associated with a lower relapse rate.
Discussion
In among 8,877 Dutch breast cancer patients treated with curative intent, this study showed a decrease in 5-year risk of relapse from 38% in 1972-1979 and 35% in 19, 20 , tumour grade, hormonal receptor status, HER2 and resection margin. The differences in histology between the periods may reflect changes in pathological assessment and classification rather than true changes. The period effect (HR=0.38) after adjustment for tumour characteristics and patient's age therefore includes the issues described above.
The 5-year risk of locoregional recurrence as first event decreased from 24% in the 1970s to 14% in the 1980s and was only 4% in [2003] [2004] . This trend was also observed in previous Dutch studies 1, 2 . We can therefore conclude that current treatment, despite the increased use of breast conserving therapy, has resulted in a good local control. In the late 1980s, a positive resection margin was identified as an important risk factor for local recurrence. This had led to more careful breast imaging before surgery, routine pathological assessment of the resection margins and re-excision in case of a positive margin 21 . In addition, adjuvant treatment 13 and a lower tumour stage 16 were associated with a decreased risk of locoregional recurrence. Breast cancer treatment is currently changing from maximal tolerable to optimally needed 22 . We recognize the importance of preventing overtreatment, yet, it is important to monitor relapse rates closely to prevent underuse of (axillary) surgery or radiotherapy 23 . This impressive improvement equals a risk reduction of 1% per year. The increasing use of systemic therapy in clinical practice has, to a large extent, contributed to the improved breast cancer outcome at a population level. Especially, since this improvement was largely independent of tumour size, nodal status and age. In contrast to systemic therapy, the strategy with respect to local treatment became less aggressive. Apparently, the less aggressive local approach could safely be implemented and possibly may have been facilitated by the availability and increased use of systemic therapy.
In the Netherlands, breast cancer screening was introduced in 1989. Previous studies showed that both a more early diagnosis and the use of systemic treatment are effective in preventing breast cancer relapse 13, 15, 16 . Discerning the impact of changed breast cancer therapy from that of a more early diagnosis goes beyond the scope of this study. Nevertheless, we attempted to evaluate the effect of a more early diagnosis by adjusting period-specific breast cancer relapse for age at diagnosis, tumour size and nodal status. Increasing tumour size and a positive lymph node status were associated with an increased risk of recurrence. Adjustment for these factors changed the period effect only slightly. Lymph node staging has, however, changed with the introduction of the sentinel node biopsy procedure in 1993 17 . As accurate staging became increasingly important for treatment planning, pathological lymph node examination was intensified. This may explain the incomplete correction for lymph node status in the present study. . This population-and hospitalbased study reflects changes in breast cancer management in practice. We studied risk of relapse in total, and for the different sites separately, providing a complete overview of trends in relapse. A limitation of this study is that in patients diagnosed in [2003] [2004] , only the first occurrence of locoregional recurrence or distant metastasis was registered. Site-specific risk estimates for locoregional recurrence and distant metastasis were, therefore, underestimated in this study. Another limitation of this study is the use of only one hospital as a historical control. Findings were, however, in line with previous Dutch studies 1, 2, [28] [29] [30] , suggesting good representativeness of our data.
Conclusion
This hospital-and population-based study demonstrates a huge improvement in breast cancer outcome when . This decrease may be attributable to a more early detection at initial diagnosis and the increased use of systemic therapy in primary breast cancer treatment. In addition, more and more effective chemotherapeutic options have become available 13 . The risk of distant metastasis is expected to decrease further because other systemic treatment options become available, for example trastuzumab 24 , and more patients are advised to be treated with systemic therapy. As prognosis improves, the impact of more and more aggressive systemic therapy on survival time will become smaller, whereas the occurrence of long-term toxic side effects will increase. Implementation of new systemic treatment options should therefore be preceded by a careful consideration of these pros and cons.
We observed no large difference in risk of second primary breast cancer between the 1970s, 1980s and 2000s, despite the increase in breast cancer incidence in the general population. In the United States, second primary breast cancer rate decreased since 1985 3, 4 . The increased risk may have been counterbalanced by the use of systemic therapy for the primary tumour 13, 25 . In addition, contralateral prophylactic mastectomy (CPM) in patients at high risk of developing a second breast cancer is increasingly performed. In the United States, the CPM rate increased from 0.4% in 1998 to 4.7% in 2007 26 . In the future, increased use of systemic therapy and CPM might comparing the patients diagnosed in the 1970s with those diagnosed in the early 2000s. Moreover, since 2004 as the number of patients selected for systemic therapy has further increased, it is likely that outcome for current patients is even better. On the one hand, this implies that there may still be room to reduce the extent of locoregional breast treatment. On the other hand, however, it may be time to reconsider the indications for systemic therapy. When the benefit of systemic therapy is only 1-2% for subgroups of patients, preventing long-term toxicities in cancer survivors may become equally or more important than preventing locoregional recurrences. This is, in our opinion, an important challenge for clinical practice and future clinical trials. 
